A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of...
Gespeichert in:
| Veröffentlicht in: | The lancet. Diabetes & endocrinology 2024-03, Vol.12 (3), p.209-214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 3 |
| container_start_page | 209 |
| container_title | The lancet. Diabetes & endocrinology |
| container_volume | 12 |
| creator | Ho, Ken K Y Fleseriu, Maria Wass, John Katznelson, Laurence Raverot, Gerald Little, Andrew S Castaño, Justo P Reincke, Martin Lopes, M Beatriz Kaiser, Ursula B Chanson, Philippe Gadelha, Mônica Melmed, Shlomo |
| description | No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas. |
| doi_str_mv | 10.1016/S2213-8587(23)00382-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04927056v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213858723003820</els_id><sourcerecordid>2929129634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-ff914dbb792cb86d21e2452edbec51644b97f6679fc64dbeac0ad68ee0b49f593</originalsourceid><addsrcrecordid>eNqFkU1v2zAMhoVhxRqk_QkbdEwPbvVhy9JpCIptLRBgh22HnQRZoloVjuVKdoD8-ylNlmtPIsiHLym-CH2m5JYSKu5-MUZ5JRvZrhi_IYRLVpEPaHFKq-bjOZbtJbrO-YUQQknDhSSf0CWXvMi0coH-rvGY4hgzOGz7MARr-hKYnIMv8RTigH1MeAzTHCaT9niAOJb6NuMp4qc5OMDTMyQz7rEZ3EHtaYg55Ct04U2f4fr0LtGf799-3z9Um58_Hu_Xm8pypabKe0Vr13WtYraTwjEKrG4YuA5sQ0Vdd6r1QrTKW1E4MJYYJyQA6WrlG8WX6Oao-2x6PaawLUvqaIJ-WG_0IUdqxVrSiB0t7OrIli1fZ8iT3oZsoe9N-dWcNVNMUaYErwvaHFGbYs4J_FmbEn0wQb-ZoA8X1ozrNxM0KX1fTiPmbgvu3PX_5AX4egSgHGUXIOlsAwwWXEhgJ-1ieGfEP2BCl0Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2929129634</pqid></control><display><type>article</type><title>A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ho, Ken K Y ; Fleseriu, Maria ; Wass, John ; Katznelson, Laurence ; Raverot, Gerald ; Little, Andrew S ; Castaño, Justo P ; Reincke, Martin ; Lopes, M Beatriz ; Kaiser, Ursula B ; Chanson, Philippe ; Gadelha, Mônica ; Melmed, Shlomo</creator><creatorcontrib>Ho, Ken K Y ; Fleseriu, Maria ; Wass, John ; Katznelson, Laurence ; Raverot, Gerald ; Little, Andrew S ; Castaño, Justo P ; Reincke, Martin ; Lopes, M Beatriz ; Kaiser, Ursula B ; Chanson, Philippe ; Gadelha, Mônica ; Melmed, Shlomo</creatorcontrib><description>No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.</description><identifier>ISSN: 2213-8587</identifier><identifier>EISSN: 2213-8595</identifier><identifier>DOI: 10.1016/S2213-8587(23)00382-0</identifier><identifier>PMID: 38301678</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adenoma - diagnosis ; Adenoma - therapy ; Cancer ; Humans ; Life Sciences ; Pituitary Neoplasms - diagnosis ; Pituitary Neoplasms - therapy ; Prognosis ; Prospective Studies ; Risk Factors</subject><ispartof>The lancet. Diabetes & endocrinology, 2024-03, Vol.12 (3), p.209-214</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-ff914dbb792cb86d21e2452edbec51644b97f6679fc64dbeac0ad68ee0b49f593</citedby><cites>FETCH-LOGICAL-c399t-ff914dbb792cb86d21e2452edbec51644b97f6679fc64dbeac0ad68ee0b49f593</cites><orcidid>0000-0002-9517-338X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38301678$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04927056$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Ho, Ken K Y</creatorcontrib><creatorcontrib>Fleseriu, Maria</creatorcontrib><creatorcontrib>Wass, John</creatorcontrib><creatorcontrib>Katznelson, Laurence</creatorcontrib><creatorcontrib>Raverot, Gerald</creatorcontrib><creatorcontrib>Little, Andrew S</creatorcontrib><creatorcontrib>Castaño, Justo P</creatorcontrib><creatorcontrib>Reincke, Martin</creatorcontrib><creatorcontrib>Lopes, M Beatriz</creatorcontrib><creatorcontrib>Kaiser, Ursula B</creatorcontrib><creatorcontrib>Chanson, Philippe</creatorcontrib><creatorcontrib>Gadelha, Mônica</creatorcontrib><creatorcontrib>Melmed, Shlomo</creatorcontrib><title>A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis</title><title>The lancet. Diabetes & endocrinology</title><addtitle>Lancet Diabetes Endocrinol</addtitle><description>No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.</description><subject>Adenoma - diagnosis</subject><subject>Adenoma - therapy</subject><subject>Cancer</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Pituitary Neoplasms - diagnosis</subject><subject>Pituitary Neoplasms - therapy</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><issn>2213-8587</issn><issn>2213-8595</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v2zAMhoVhxRqk_QkbdEwPbvVhy9JpCIptLRBgh22HnQRZoloVjuVKdoD8-ylNlmtPIsiHLym-CH2m5JYSKu5-MUZ5JRvZrhi_IYRLVpEPaHFKq-bjOZbtJbrO-YUQQknDhSSf0CWXvMi0coH-rvGY4hgzOGz7MARr-hKYnIMv8RTigH1MeAzTHCaT9niAOJb6NuMp4qc5OMDTMyQz7rEZ3EHtaYg55Ct04U2f4fr0LtGf799-3z9Um58_Hu_Xm8pypabKe0Vr13WtYraTwjEKrG4YuA5sQ0Vdd6r1QrTKW1E4MJYYJyQA6WrlG8WX6Oao-2x6PaawLUvqaIJ-WG_0IUdqxVrSiB0t7OrIli1fZ8iT3oZsoe9N-dWcNVNMUaYErwvaHFGbYs4J_FmbEn0wQb-ZoA8X1ozrNxM0KX1fTiPmbgvu3PX_5AX4egSgHGUXIOlsAwwWXEhgJ-1ieGfEP2BCl0Q</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Ho, Ken K Y</creator><creator>Fleseriu, Maria</creator><creator>Wass, John</creator><creator>Katznelson, Laurence</creator><creator>Raverot, Gerald</creator><creator>Little, Andrew S</creator><creator>Castaño, Justo P</creator><creator>Reincke, Martin</creator><creator>Lopes, M Beatriz</creator><creator>Kaiser, Ursula B</creator><creator>Chanson, Philippe</creator><creator>Gadelha, Mônica</creator><creator>Melmed, Shlomo</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-9517-338X</orcidid></search><sort><creationdate>202403</creationdate><title>A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis</title><author>Ho, Ken K Y ; Fleseriu, Maria ; Wass, John ; Katznelson, Laurence ; Raverot, Gerald ; Little, Andrew S ; Castaño, Justo P ; Reincke, Martin ; Lopes, M Beatriz ; Kaiser, Ursula B ; Chanson, Philippe ; Gadelha, Mônica ; Melmed, Shlomo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-ff914dbb792cb86d21e2452edbec51644b97f6679fc64dbeac0ad68ee0b49f593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adenoma - diagnosis</topic><topic>Adenoma - therapy</topic><topic>Cancer</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Pituitary Neoplasms - diagnosis</topic><topic>Pituitary Neoplasms - therapy</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ho, Ken K Y</creatorcontrib><creatorcontrib>Fleseriu, Maria</creatorcontrib><creatorcontrib>Wass, John</creatorcontrib><creatorcontrib>Katznelson, Laurence</creatorcontrib><creatorcontrib>Raverot, Gerald</creatorcontrib><creatorcontrib>Little, Andrew S</creatorcontrib><creatorcontrib>Castaño, Justo P</creatorcontrib><creatorcontrib>Reincke, Martin</creatorcontrib><creatorcontrib>Lopes, M Beatriz</creatorcontrib><creatorcontrib>Kaiser, Ursula B</creatorcontrib><creatorcontrib>Chanson, Philippe</creatorcontrib><creatorcontrib>Gadelha, Mônica</creatorcontrib><creatorcontrib>Melmed, Shlomo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The lancet. Diabetes & endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ho, Ken K Y</au><au>Fleseriu, Maria</au><au>Wass, John</au><au>Katznelson, Laurence</au><au>Raverot, Gerald</au><au>Little, Andrew S</au><au>Castaño, Justo P</au><au>Reincke, Martin</au><au>Lopes, M Beatriz</au><au>Kaiser, Ursula B</au><au>Chanson, Philippe</au><au>Gadelha, Mônica</au><au>Melmed, Shlomo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis</atitle><jtitle>The lancet. Diabetes & endocrinology</jtitle><addtitle>Lancet Diabetes Endocrinol</addtitle><date>2024-03</date><risdate>2024</risdate><volume>12</volume><issue>3</issue><spage>209</spage><epage>214</epage><pages>209-214</pages><issn>2213-8587</issn><eissn>2213-8595</eissn><abstract>No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38301678</pmid><doi>10.1016/S2213-8587(23)00382-0</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9517-338X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2213-8587 |
| ispartof | The lancet. Diabetes & endocrinology, 2024-03, Vol.12 (3), p.209-214 |
| issn | 2213-8587 2213-8595 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04927056v1 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adenoma - diagnosis Adenoma - therapy Cancer Humans Life Sciences Pituitary Neoplasms - diagnosis Pituitary Neoplasms - therapy Prognosis Prospective Studies Risk Factors |
| title | A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T08%3A59%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20proposed%20clinical%20classification%20for%20pituitary%20neoplasms%20to%20guide%20therapy%20and%20prognosis&rft.jtitle=The%20lancet.%20Diabetes%20&%20endocrinology&rft.au=Ho,%20Ken%20K%20Y&rft.date=2024-03&rft.volume=12&rft.issue=3&rft.spage=209&rft.epage=214&rft.pages=209-214&rft.issn=2213-8587&rft.eissn=2213-8595&rft_id=info:doi/10.1016/S2213-8587(23)00382-0&rft_dat=%3Cproquest_hal_p%3E2929129634%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2929129634&rft_id=info:pmid/38301678&rft_els_id=S2213858723003820&rfr_iscdi=true |